Beijing lingfu Biotechnology Co., Ltd. recently completed a pre-A financing round of more than 200 million yuan. Guoshou equity led the investment, Junlian equity jointly led the investment, and Chang development equity, Puhua equity, Saifu medicine and other institutions followed the investment. Probe capital acted as financial advisor. This financing round is mainly used for the development of an experimental animal resource base and a laboratory. Lingfu’s biology was incubated and established by Beijing Saifu Pharmaceutical Research Institute Co., Ltd., Beijing Renyuan Xinsheng Biotechnology Co., Ltd. and the team of experimental animal industry experts. Previously, lingfu biology has achieved nearly 50 million yuan of angel funding. Experimental animals and model animals, as carriers, pass through the important links in drug development and are the key support of the biomedical industry. The coverage and quality of animal models directly affects the success rate of subsequent clinical trials. Lingfu Biology is committed to becoming the leading scientific research service provider integrating the whole industry chain of laboratory animals, the whole industry chain of animal models and high value-added scientific research services in China.